Overview

TDM of Generic Lopinavir/Ritonavir 200/50 mg

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

Evaluating the bioavailibility safety and efficacy of the generic LPV/RTV 200/50 mg tablet formulation in a 400/100 mg BID dose in Thai HIV infected individuals.

Phase:

Phase 2

Details

Lead Sponsor:

The HIV Netherlands Australia Thailand Research Collaboration

Collaborator:

The Government Pharmaceutical Organization

Treatments:

Lopinavir
Ritonavir